Concepedia

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

Yongfeng Yu, Qisen Guo, Yongchang Zhang, Jian Fang, Diansheng Zhong, Baogang Liu, Pinhua Pan, Dongqing Lv, Lin Wu, Yanqiu Zhao,

The Lancet Respiratory Medicine · 2024 · 21 citations · 9 references

DOI

Concepts

References

9

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Julian R. Molina, Ping Yang, Stephen D. Cassivi et al. · Mayo Clinic Proceedings · 2008 · 2.9K citations

, , +14

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 997 citations · Full text

, , +15

<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression

Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman et al. · Journal of Clinical Oncology · 2016 · 688 citations · Full text

, , +17

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

Alexa B. Schrock, Garrett M. Frampton, James Suh et al. · Journal of Thoracic Oncology · 2016 · 381 citations · Full text

, , +17

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Shun Lü, Jian Fang, Xingya Li et al. · The Lancet Respiratory Medicine · 2021 · 204 citations

, , +11